NP / PA
Beacon Orthopaedics & Sports Medicine, LTD
Beacon Orthopaedics & Sports Medicine, LTD was paid $1.18M by Medicaid between Jan 2018 and Dec 2024, across 31 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 18% of everything it billed.
33Billing provider infoBEACON ORTHOPAEDICS & SPORTS MEDICINE, LTD
CINCINNATI, OH 45241
CINCINNATI, OH 45241
33aNPI1386670065assigned 06/24/2006
33bProvider typePhysician Assistant
28Total paid$1.18M
24GClaims48,208
24DCodes billed31
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Physician Assistant providers in Ohio
Rank by total paid#24 of 176
Median peer was paid$13K
This provider vs. median91×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 207 | $873.48 | |
| 2019 | 33 | $734.04 | |
| 2021 | 1,277 | $33K | |
| 2022 | 5,031 | $159K | |
| 2023 | 18,311 | $440K | |
| 2024incomplete | 23,349 | $546K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 7,862 | 6,705 | $215K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 4,768 | 4,060 | $203K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 14% | 9,754 | 3,590 | $168K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 11% | 2,838 | 2,548 | $135K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 8.4% | 1,591 | 1,530 | $99K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 7.3% | 1,490 | 1,343 | $87K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 7.3% | 6,896 | 2,460 | $86K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 7.0% | 5,624 | 2,161 | $82K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 5.3% | 3,980 | 1,565 | $63K |
| 20610 | 1.1% | 479 | 331 | $13K | |
| 95886 | <1% | 148 | 133 | $6K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 828 | 658 | $4K |
19 more codes
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 489 | $3K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 344 | $2K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 232 | $2K |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 120 | $2K |
| 20611 | <1% | 43 | $2K | |
| 73630 | <1% | 105 | $2K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 40 | $2K |
| 99243 | <1% | 27 | $1K | |
| 97161 | <1% | 12 | $871.44 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 130 | $696.07 |
| 73564 | <1% | 34 | $633.93 | |
| 72110 | <1% | 25 | $618.13 | |
| 73610 | <1% | 43 | $552.19 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 18 | $352.16 |
| 20552 | <1% | 25 | $305.06 | |
| 73140 | <1% | 13 | $166.81 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 198 | $127.49 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 28 | $2.15 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 24 | $0.03 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYUCKMAN, TIMOTHY (CEO)